Clinical Trials

Acute Myeloid Leukemia

A Phase III, double-blind, placebo-controlled, multicenter, randomized study of pracinostat in combination with azacitidine in patients 18 years or older with newly diagnosed acute myeloid leukemia unfit for standard induction chemotherapy
NCT#03151408  |  Jatin Rana, MD

Advanced Solid Tumors or Lymphoma

Targeted drug therapy directed by genetic testing in treating patients with advanced refractory tumors.
NCT#02465060  |  Borys Hrinczenko, MD

Benign Hematology

A multi-center, multi-national, observational registry with enrollment of patients who are diagnosed with PNH and also PNH patients not receiving Soliris therapy.
NCT#01374360  |  Borys Hrinczenko, MD

Bladder

A PhaseII trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer. 
NCT#02844816  |  Jatin Rana, MD

Breast

Randomized Phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer. For HER2 negative, and ER/PR positive or negative breast cancer.
For Stage II or Stage III, HER2 negative, and ER/PR positive or negative breast cancer.
NCT#02750826   |  Jatin Rana, MD

A single arm Phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer. 
NCT#02668666   |  Jatin Rana, MD

A Phase II study of pembrolizuamb plus fulvestrant in hormone receptor positive, HER-2 negative advance/metastatic breast cancer patients.
NCT#03393845   |  Jatin Rana, MD

A randomized, double-blind, parallel group, placebo-controlled multi-center Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment AND neoadjuvant OR adjuvant chemotherapy. 
NCT#02032823   |  Jatin Rana, MD

A randomized, double-blind, Phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple-negative breast cancer followed by adjuvant continuation of atezolizumab or placebo.
NCT#03281954   |  Jatin Rana, MD

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/neu negative breast cancer. 
NCT#01674140  |  Jatin Rana, MD

A randomized, Phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy. 
NCT#02954874 | Jatin Rana, MD

Colon

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with Stage III colon cancer and deficient DNA mismatch repair
NCT#02912559 |  Jatin Rana, MD

Essential Thrombocythemia

Prospective, longitudinal, non-interventional study of disease burden and treatment of patients with low-risk myelofibrosis OR high-risk essential thrombocytemia (ET) OR ET patients receiving ET-directed therapy (MOST Trial). 
NCT#02953704  |  Borys Hrinczenko, MD

Gastric, Gastro-Esophageal Junction

A Phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastro-esophageal junction adenocarcinoma. 
NCT#03283761  |  Jatin Rana, MD

Lung

A randomized, double-blind, placebo-controlled pilot study of an oral, selective peripheral opioid receptor antagonist in advanced non-small cell lung cancer (Adenocarcinoma) Stage IIIB or Stage IV.
NCT#02912559  |  Borys Hrinczenko, MD

A Phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable Stage IIIA/IIIB non-small cell lung cancer. 
NCT#03285321  |  Borys Hrinczenko, MD

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. (for non-small cell lung cancer)
NCT#02517398  |  Borys Hrinczenko, MD

Lymphoma

Targeted drug therapy directed by genetic testing in treating patients with advanced refractory tumors.
NCT#02465060 | Jatin Rana, MD

An open-label phase ½ study of INCB039110 (Itacitinib) in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
NCT#02760485   |  Jatin Rana, MD

Multiple Myeloma

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
NCT#01863550 |  Jatin Rana, MD

Targeted drug therapy directed by genetic testing in treating patients with advanced refractory tumors.
NCT#02465060 | Jatin Rana, MD

A Phase 2/3, randomized, open-label study comparing oral ixazomib/dexamethasone and oral pomalidomide/dexamethasone in relapsed and/or refractory multiple myeloma.
NCT#03170882  |  Jatin Rana, MD

Myelodysplastic Syndrome (MDS) or Myelproliferative Overlap Disorder

An observational study of patients with newly diagnosed (within 2 months) MDS or AML. Patients are excluded it they have received treatment with active agents for MDS or AML prior to ICF date. Supportive care treatments are allowed. 
NCT#01688011   |  Borys Hrinczenko, MD

Myelodysplastic Syndrome (MDS) including sub-type Chronic Myelomonocytic Leukemia (CMML)

The National Myelodysplastic Syndromes (MDS) Study.  A multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). 
NCT#02775383  |  Jatin Rana, MD

Myelofibrosis

Prospective, longitudinal, non-interventional study of disease burden and treatment of patients with low-risk myelofibrosis OR high-risk essential thrombocytemia (ET) OR ET patients receiving ET-directed therapy (MOST Trial)
NCT#02953704  |  Borys Hrinczenko, MD

Prostate

A phase II, double-blinded, placebo-controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer
NCT#03371719  |  Jatin Rana, MD

Symptom Management

Symptom Management (Strategies) Among Cancer patients with possible Reflexology, or Meditative Practices (gentle yoga, meditation and breathing exercises)
NCT#02759146   |   contact 517 975-9547